Free Trial
NASDAQ:BDTX

Black Diamond Therapeutics Q2 2025 Earnings Report

Black Diamond Therapeutics logo
$3.13 -0.08 (-2.49%)
Closing price 07/18/2025 04:00 PM Eastern
Extended Trading
$3.21 +0.08 (+2.68%)
As of 07/18/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Black Diamond Therapeutics EPS Results

Actual EPS
N/A
Consensus EPS
-$0.26
Beat/Miss
N/A
One Year Ago EPS
N/A

Black Diamond Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Black Diamond Therapeutics Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Wednesday, August 6, 2025
Conference Call Time
4:00PM ET

Conference Call Resources

Black Diamond Therapeutics Earnings Headlines

[No Brainer Gold Play]: “Show me a better investment.”
A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the quiet buildup behind the scenes. Now, in just days, the floodgates are set to open. The greatest investor of all time could validate what Garrett Goggin has been saying for months: Gold is entering a once-in-a-generation mania. Front-running Buffett has never been more urgent — and four tiny miners could be your ticket to 100X gains.
See More Black Diamond Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Black Diamond Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Black Diamond Therapeutics and other key companies, straight to your email.

About Black Diamond Therapeutics

Black Diamond Therapeutics (NASDAQ:BDTX) is a precision oncology company focused on the discovery and development of targeted therapies for genetically defined cancers. Founded in 2016 and headquartered in South San Francisco, the company has built its research programs around the concept of allele-specific targeting, seeking to design small molecules that selectively inhibit mutant proteins driving tumor growth while sparing their normal counterparts. By leveraging deep insights into tumor genomics and structure-based drug design, Black Diamond aims to address mutations that have thus far been difficult to drug.

The company’s proprietary functional genomics platform integrates biophysical, cellular and in vivo data to identify clinically relevant tumor alleles and guide the design of precision inhibitors. Black Diamond’s lead candidate, BDTX-189, is an inhibitor of ERBB family exon 20 insertion mutations and is being evaluated in patients with advanced solid tumors. Its second clinical asset, BDTX-063, targets canonical EGFR mutations in non-small cell lung cancer, and the preclinical pipeline includes BDTX-1535, an allosteric inhibitor of KRAS G12C, along with a discovery-stage program aiming at novel oncogenic drivers.

Black Diamond conducts its clinical trials across the United States and collaborates with research centers in Europe and Asia to accelerate patient enrollment and gather diverse real-world data. The company maintains partnerships with academic institutions and leverages external expertise to refine its precision oncology approach. Through these global efforts, Black Diamond seeks to bring new therapeutic options to patients whose tumors harbor specific, actionable mutations.

Under the leadership of President and Chief Executive Officer Reid Huber, Black Diamond has grown its team of scientific, clinical and regulatory experts to support its mission. The company’s board and management team combine experience from major biopharmaceutical firms, start-ups and leading academic medical centers, reflecting a commitment to both rigorous science and patient-centric drug development. As Black Diamond advances its pipeline, it remains dedicated to transforming the treatment landscape for patients with genetically defined cancers.

View Black Diamond Therapeutics Profile

More Earnings Resources from MarketBeat